Invokana was Johnson & Johnson's big bet on the vast market for type 2 diabetes drugs. While sales soared, @Reuters found, executives rebuffed their safety experts’ advice to warn regulators about a dangerous complication https://t.co/hMP8EZf4VE pic.twitter.com/gCB1YCxeo5— Reuters (@Reuters) December 8, 2021
(SocialLY brings you all the latest breaking news, fact checks and information from social media world, including Twitter (X), Instagram and Youtube. The above post contains publicly available embedded media, directly from the user's social media account and the views appearing in the social media post do not reflect the opinions of LatestLY.)













Quickly


